Evolving concepts and a new approach for management of hyperlipidemia
Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Baylor College of Medicine, Texas, U.S.A.
1 Correspondence: Christie Ballantyne, MD, Section of Atherosclerosis and Lipoprotein Research, Baylor College of Medicine, 6565 Fannin Street, M.S. A-601, Suite A654B, Houston, Texas 77030, U.S.A.
Abstract
Although treatment of modifiable risk factors for coronary heart disease (CHD), including hypertension and hyperlipidemia, constitutes a large proportion of visits to family practitioners, most surveys reveal that neither hypertension nor hyperlipidemia are treated to targets specified by national guidelines. Current recommendations for the management of hypertension have evolved from earlier recommendations to titrate to high-dose monotherapy if needed to an emphasis on combination therapy, which can achieve greater efficacy than monotherapy without the increased side effects associated with a high-dose single agent.
Key Words: Cholesterol-lowering drugs combination therapy ezetimibe hyperlipidemis treatment